Talmapimod NEW
| Price | $48 | $117 | $187 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-29 |
Product Details
| Product Name: Talmapimod | CAS No.: 309913-83-5 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2025/04/29 |
Product Introduction
Bioactivity
| Name | Talmapimod |
| Description | Talmapimod (SCIO-469) is a selective, orally active, ATP-competitive p38α inhibitor with IC50 values of 9 nM for p38α and 90 nM for p38β. Talmapimod exhibits at least 2000-fold selectivity over a panel of 20 kinases, including other MAPKs. |
| In vitro | phosphorylation of p38 MAPK inhibited by Talmapimod (100-200 nM; 1 hour) in MM cells[1].In human whole blood, LPS-induced TNF-a production inhibited by Talmapimod [2]. Talmapimod decreases constitutive p38alpha MAPK phosphorylation of both 5T2MM and 5T33MM cells[3]. |
| In vivo | Talmapimod (SCIO-469), targeting p38α MAPK, reduces myeloma burden and prevents myeloma bone disease[2]. In 5T2MM and 5T33MM models, it inhibits multiple myeloma growth and bone diseases[3]. Administered at 10-90 mg/kg orally, twice daily for 14 days, Talmapimod dose-dependently diminishes tumor growth and decreases the weight of palpable tumors at termination[4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 95 mg/mL (185.19 mM), Sonication is recommended. |
| Keywords | tumor | Talmapimod | SCIO469 | SCIO 469 | phosphorylation | p38β | p38α | p38MAPK | p38 MAPK | myeloma | multiple | Inhibitor | inhibit | Hsp27 | cytotoxicity | cells |
| Inhibitors Related | Adezmapimod | Exarafenib | Doramapimod | VX-702 | Bakuchiol | p38α inhibitor 3 | SB 202190 | (-)-Bornyl acetate | MW-150 | (E)-Ferulic acid methyl ester | p38-α MAPK-IN-1 | Nisin Z |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
CAS:144822-48-0
$0.00 / 5mg
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $48.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-04-29 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY